JW Women's Health -- Sign In Summary and Comment. Screen for activated protein c resistance Isn t CostEffective. activated protein c resistance assay when applied in the general population. http://womens-health.jwatch.org/cgi/content/full/1997/401/10
Extractions: All customers have full-text access to the Journal Watch publication(s) to which they have a subscription. Other registered users have access to Journal Watch Online content older than six months and may request e-mail notification of current contents. Subscribers and Registered Users User Name Password If you are a subscriber using Journal Watch Online for the first time you must activate and choose a password Remember my user name and password. Forgotten your password? If you do not use cookies sign in here (After you click the 'Sign In' button you may have to wait for several seconds. Thank you for your patience.)
NEJM -- Resistance To Activated Protein C Correspondence from The New England Journal of Medicine resistance to activated protein C Number 2. Next. resistance to activated protein C. Since this article has no abstract, we have provided an by Svensson and Dahlback on resistanceto activated protein C (APC) (Feb http://www.nejm.org/cgi/content/short/331/2/129
Extractions: Add to Personal Archive Add to Citation Manager E-mail When Cited ... PubMed Citation To the Editor: The article by Svensson and Dahlback on resistance to activated protein C (APC) (Feb. 24 issue) postulates that there is a genetically determined defect in anticoagulation characterized by resistance to APC. The authors subsequently found the anticoagulant cofactor that corrects inherited APC resistance to be identical to unactivated factor V. I believe that these findings could also be due to hyperhomocysteinemia. It has been demonstrated that hyperhomocysteinemia is an independent risk factor for vascular disease . It was previously demonstrated that homocysteine induced a vascular-endothelial-cell activator that led to the activation of factor Full Text of this Article References
Extractions: protein C (resistance to activated protein C) Resistance to the anticoagulant effects of activated protein C (APC) (Factor V Leiden heterozygous*) is common (1): APC resistance is usually due to a single point mutation in one or both of the protein C genes. The mutation reduces the susceptibility of factor V to cleavage by APC. There is increasing evidence that individuals with two or more laboratory characterisable thrombophilic abnormalities (or who are homozygous for either factor V Leiden or prothrombin G20210A) are at a greater risk of thrombosis than those in whom there is a single gene abnormality (1). * Factor V Leiden homozygous individuals have an 80x risk of venous thromboembolism Reference: (1) British Heart Foundation (Factfile 2/2002). Thrombophilia (2) Rogier, MB. et al. (1994). Mutation in blood coaulation factor V associated with resistance to activated protein C. Nature, 369, 64-7. (3) Drugs and Therapeutics Bulletin (1995), 33 (1), 6-8.
Resistance To Activated Protein C - General Practice Notebook resistance to activated protein C. et al. (1994). Mutation in blood coaulation factor V associated with resistance to activated protein C. Nature, 369, 647. http://www.gpnotebook.co.uk/cache/1731526712.htm
Extractions: resistance to activated protein C Resistance to the anticoagulant effects of activated protein C (APC) (Factor V Leiden heterozygous*) is common (1): APC resistance is usually due to a single point mutation in one or both of the protein C genes. The mutation reduces the susceptibility of factor V to cleavage by APC. There is increasing evidence that individuals with two or more laboratory characterisable thrombophilic abnormalities (or who are homozygous for either factor V Leiden or prothrombin G20210A) are at a greater risk of thrombosis than those in whom there is a single gene abnormality (1). * Factor V Leiden homozygous individuals have an 80x risk of venous thromboembolism Reference: (1) British Heart Foundation (Factfile 2/2002). Thrombophilia (2) Rogier, MB. et al. (1994). Mutation in blood coaulation factor V associated with resistance to activated protein C. Nature, 369, 64-7. (3) Drugs and Therapeutics Bulletin (1995), 33 (1), 6-8.
NEJM -- Resistance To Activated Protein C Correspondence from The New England Journal of Medicine resistance to activated protein C. Next Next. resistance to activated protein C. http://content.nejm.org/cgi/content/short/331/2/129
Extractions: Add to Personal Archive Add to Citation Manager E-mail When Cited ... PubMed Citation To the Editor: The article by Svensson and Dahlback on resistance to activated protein C (APC) (Feb. 24 issue) postulates that there is a genetically determined defect in anticoagulation characterized by resistance to APC. The authors subsequently found the anticoagulant cofactor that corrects inherited APC resistance to be identical to unactivated factor V. I believe that these findings could also be due to hyperhomocysteinemia. It has been demonstrated that hyperhomocysteinemia is an independent risk factor for vascular disease . It was previously demonstrated that homocysteine induced a vascular-endothelial-cell activator that led to the activation of factor Full Text of this Article References
Procedure Activated Protein C Resistent FV also known as APC Resistant Factor V, protein C resistance Assay, Factor V Leiden, APCFV , activated protein C Resistant FVA, Blood. SPECIAL COAGULATION LAB, http://health.ucsd.edu/labref/P321.html
Extractions: UNIVERSITY OF CALIFORNIA, SAN DIEGO CLINICAL LABORATORIES Activated Protein C Resistent FV Specimen Type: also known as APC Resistant Factor V, Protein C Resistance Assay, Factor V Leiden, APCFV , Activated Protein C Resistant FVA Blood SPECIAL COAGULATION LAB specimen requirements: Blue Top normal or reference ranges: Category LOW HIGH UNITS Normal unit of measure: Normal/Abnormal ideal sample: 2.7 mL Whole Blood, 5.0 mL blue top absolute minimum amount: 2.4 mL Whole Blood The following substances can adversely affect the results: Clots in Specimen, Improper Line Draw request test on form: Hematology Test Request ( 151-204 ) Miscellaneous ( 151-858 ) order/entry screen(s): Hematology/Coagulation method: Optical Clot Detection stat frequency : Monday - Friday, 0830-1630 routine turn around time: 1 Week For Hillcrest deliver to: SCRAP : Specimen Central Receiving and Processing, room 2-117 For Thornton deliver to: Hematology : Processing Desk, 1st floor, Hospital, room 1-013 Special Instructions: Assay is not affected by heparin, coumadin, or lupus anticoagulant.
Extractions: Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Genome Links GEO Links HomoloGene Links Nucleotide Links OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links UniSTS Links Show: Sort Author Journal Pub Date Text File Clipboard E-mail Order
Activated Protein C (APC) Resistance activated protein C (APC) resistance. . REQUESTING AND COLLECTING. Collection Tube MUST be full. Place on ice if unable to deliver to laboratory within. http://www.sydpath.stvincents.com.au/spec_db/SydPathTestDetailsPage17.html
CLR [ Index Of Tests/rare Tests ] Tests/Rare Tests. Below are the results from your search activated protein Cresistance (APCR). ARUP Inc 500 Chipeta Way Salt Lake http://www.clr-online.com/cgi-bin/2003/testlisting.asp?ID=1495&Test=Activated pr
Extractions: American Red Cross Blood Services - New England Region Name: Activated Protein C Major Products Available: Drotrecogin alpha (activated) Description/Contents Drotrecogin alpha (activated) is a recombinant form of human activated protein C (APC) that is manufactured as an inactive zymogen and is enzymatically activated by cleavage with thrombin, then purified using monoclonal antibodies. APC exerts an anticoagulant effect, along with its co-factor protein S, by inactivating Factors Va and VIIIa, two critical pro-coagulants that lead to thrombin formation. Thrombin binds to thrombomodulin on endothelial cells at and adjacent to the site of vascular injury which stimulated the coagulation process. Thrombomodulin serves as a cofactor for the conversion of protein C, present in the plasma, by thrombin to activated protein C. APC also inhibits tumor necrosis factor production by monocytes, blocks leukocyte adhesion to selectins and limits thrombin-induced microvascular damage. Discovery of an APC-resistant state, hereditary Factor V Leiden, which leads to increased susceptibility to thrombosis, has led to extensive laboratory testing and an occasional diagnosis of APC-resistance in some cases of thrombophilia or venous thrombosis.
